Is Electromotive Mitomycin C an Alternative Treatment for Frail Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Failed Intravesical BCG?

Abstract

Total of 67 patients had pathological T3a disease. Biochemical recurrence was defined as PSA ≥ 0.2. 32 (48%) patients had biochemical recurrence. These patients had salvage treatment at PSA relapse rather than adjuvant. 18 out of 32 patients received radiotherapy before their PSA reached 2 and 1 patient had subcapsular orchidectomy. Overall 3 out of 37 patients had progressive disease (1 lymph node, 2 bone metastases) requiring hormonal treatment. Hence in our study 96% had progression free survival and 100% disease specific survival. 5year biochemical recurrence free survival was 67%. The overall survival was 94%. Conclusions: Surgery alone can be sufficient for pT3a prostate cancer in selected cases. Salvage radiotherapy offers additional advantage to the patients without compromising oncological outcome. Hence, we may offer surgery as a first line of multimodality therapy to all suspected pT3a patients over radiotherapy ± hormones.

Intravesical radiofrequency-induced hyperthermia combined with chemotherapy for non-muscle-invasive bladder cancer

“…However, in a different paper no difference in response rate was seen in CIS patients failing or responding to BCG [37]. Also in intermediate and high risk patients in general, studies show no effect of previous BCG failure [38,39]. Arends et al describe their 10-year experience in a cohort of 160 patients in which 81% of the subjects was previously treated with BCG.…”

Radiofrequency-Induced Thermo-Chemotherapy Effect (Rite) for Non Muscle Invasive Bladder Cancer Treatment: Current Role and Perspectives

“…Most papers concerning RITE describe experience with chemo-hyperthermia alone, as a single-arm study for intermediate and high-risk NMIBC patients. The overall recurrence rates vary from 16% to 89% (9–10–11–12–13–14–15–16–17–18–19–20–21–22–23–24–25), depending on patient selection and protocol treatment. Overall progression rates vary from 0% to 36%; however, when only studies with a follow-up of >2 years and adequate definition for progression are included, a progression rate of 0% to 11.9% remains (Tab.…”